RxDoctor Payments DataLook up a doctor →

Gregory Mauldin, MD

Critical Care Medicine · Snellville, GANPI 1871673749

Payments from drug & device makers

$221,226in general payments, 2019–2025

Across 982 payments — averaging $225.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$86K
  • Mylan Specialty L.p.$49K
  • Regeneron Healthcare Solutions, Inc.$29K
  • AstraZeneca$25K
  • Johnson & Johnson$16K
  • Sanofi$5K
  • plus $12K from 50 others

What the payments were for

  • Consulting fees$3,0181%
  • Speaking & faculty fees$166,59075%
  • Travel & lodging$28,80113%
  • Food & beverage$22,47310%
  • Education$3440%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$221,226 in reported general payments places this provider in the 95th percentile of 265 critical care medicine providers in Georgia.

See all critical care medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$158,438
Medicare patients
341
Services billed
2,973

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate59$745,329
Trelegy ElliptaFluticasone/Umeclidin/Vilanter384$392,586
Breztri AerosphereBudesonide/Glycopyr/Formoterol116$104,691
Prolastin CAlpha-1-Proteinase Inhibitor13$100,323
NucalaMepolizumab14$52,318
Dupixent SyringeDupilumab14$51,704
EliquisApixaban53$41,642
XareltoRivaroxaban44$35,062
XolairOmalizumab12$32,757
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr26$30,816
SymbicortBudesonide/Formoterol Fumarate43$15,865
Breo ElliptaFluticasone/Vilanterol11$5,030
Arnuity ElliptaFluticasone Furoate11$5,027
Albuterol Sulfate HfaAlbuterol Sulfate135$4,666
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$4,346

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev$4,445$745,32959 claims
GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$86,158$485,777446 claims
AstraZenecaBreztri Aerosphere, Symbicort$24,958$120,556159 claims
Grifols USA, LLCProlastin C$551$100,32313 claims
PfizerEliquis$190$41,64253 claims
Johnson & JohnsonXarelto$16,133$35,06244 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 265 critical care medicine providers in Georgia.

Other critical care medicine in Snellville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →